Pharmacological treatment of early multiple sclerosis

Olaf Stuve, Jeffrey L. Bennett, Bernhard Hemmer, Heinz Wiendl, Michael K. Racke, Amit Bar-Or, Wei Hu, Robert Zivadinov, Martin S. Weber, Scott S. Zamvil, Maria Fides Manago Pacheco, Til Menge, Hans Peter Hartung, Bernd C. Kieseier, Elliot Frohman

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Currently, six medications are approved by the US FDA for the treatment of relapsing forms of multiple sclerosis (MS). In contrast, no pharmacological agent has proved to be effective in patients with secondary-progressive MS without relapses, or in patients with primary-progressive MS. One of the principal issues concerning an optimal pharmacotherapy for relapsing forms of MS is the optimal time of treatment initiation. There is now an almost universal consensus among MS experts that many patients will benefit from early therapy. However, several formidable challenges exist in identifying individuals who will benefit versus those who will do well without intervention. How do we define early MS and what clinical and paraclinical markers may be useful in defining the timing and nature of therapy? Do patients with a benign form of MS require therapy or are they exposed unnecessarily to adverse effects of our currently available medications? How do we identify disease progression and treatment failures? This review discusses these issues and outlines the evidence for application of 'early' treatment in patients with relapsing forms of MS.

Original languageEnglish (US)
Pages (from-to)73-83
Number of pages11
JournalDrugs
Volume68
Issue number1
StatePublished - 2008

Fingerprint

Drug therapy
Multiple Sclerosis
Pharmacology
Chronic Progressive Multiple Sclerosis
Therapeutics
Secondary Prevention
Treatment Failure
Disease Progression
Biomarkers
Recurrence
Drug Therapy

Keywords

  • Interferon beta 1a, therapeutic use
  • Interferon beta 1b, therapeutic use
  • Multiple sclerosis, treatment

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Stuve, O., Bennett, J. L., Hemmer, B., Wiendl, H., Racke, M. K., Bar-Or, A., ... Frohman, E. (2008). Pharmacological treatment of early multiple sclerosis. Drugs, 68(1), 73-83.

Pharmacological treatment of early multiple sclerosis. / Stuve, Olaf; Bennett, Jeffrey L.; Hemmer, Bernhard; Wiendl, Heinz; Racke, Michael K.; Bar-Or, Amit; Hu, Wei; Zivadinov, Robert; Weber, Martin S.; Zamvil, Scott S.; Pacheco, Maria Fides Manago; Menge, Til; Hartung, Hans Peter; Kieseier, Bernd C.; Frohman, Elliot.

In: Drugs, Vol. 68, No. 1, 2008, p. 73-83.

Research output: Contribution to journalArticle

Stuve, O, Bennett, JL, Hemmer, B, Wiendl, H, Racke, MK, Bar-Or, A, Hu, W, Zivadinov, R, Weber, MS, Zamvil, SS, Pacheco, MFM, Menge, T, Hartung, HP, Kieseier, BC & Frohman, E 2008, 'Pharmacological treatment of early multiple sclerosis', Drugs, vol. 68, no. 1, pp. 73-83.
Stuve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A et al. Pharmacological treatment of early multiple sclerosis. Drugs. 2008;68(1):73-83.
Stuve, Olaf ; Bennett, Jeffrey L. ; Hemmer, Bernhard ; Wiendl, Heinz ; Racke, Michael K. ; Bar-Or, Amit ; Hu, Wei ; Zivadinov, Robert ; Weber, Martin S. ; Zamvil, Scott S. ; Pacheco, Maria Fides Manago ; Menge, Til ; Hartung, Hans Peter ; Kieseier, Bernd C. ; Frohman, Elliot. / Pharmacological treatment of early multiple sclerosis. In: Drugs. 2008 ; Vol. 68, No. 1. pp. 73-83.
@article{358d41aad12d45c0aa696710e7afa970,
title = "Pharmacological treatment of early multiple sclerosis",
abstract = "Currently, six medications are approved by the US FDA for the treatment of relapsing forms of multiple sclerosis (MS). In contrast, no pharmacological agent has proved to be effective in patients with secondary-progressive MS without relapses, or in patients with primary-progressive MS. One of the principal issues concerning an optimal pharmacotherapy for relapsing forms of MS is the optimal time of treatment initiation. There is now an almost universal consensus among MS experts that many patients will benefit from early therapy. However, several formidable challenges exist in identifying individuals who will benefit versus those who will do well without intervention. How do we define early MS and what clinical and paraclinical markers may be useful in defining the timing and nature of therapy? Do patients with a benign form of MS require therapy or are they exposed unnecessarily to adverse effects of our currently available medications? How do we identify disease progression and treatment failures? This review discusses these issues and outlines the evidence for application of 'early' treatment in patients with relapsing forms of MS.",
keywords = "Interferon beta 1a, therapeutic use, Interferon beta 1b, therapeutic use, Multiple sclerosis, treatment",
author = "Olaf Stuve and Bennett, {Jeffrey L.} and Bernhard Hemmer and Heinz Wiendl and Racke, {Michael K.} and Amit Bar-Or and Wei Hu and Robert Zivadinov and Weber, {Martin S.} and Zamvil, {Scott S.} and Pacheco, {Maria Fides Manago} and Til Menge and Hartung, {Hans Peter} and Kieseier, {Bernd C.} and Elliot Frohman",
year = "2008",
language = "English (US)",
volume = "68",
pages = "73--83",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Pharmacological treatment of early multiple sclerosis

AU - Stuve, Olaf

AU - Bennett, Jeffrey L.

AU - Hemmer, Bernhard

AU - Wiendl, Heinz

AU - Racke, Michael K.

AU - Bar-Or, Amit

AU - Hu, Wei

AU - Zivadinov, Robert

AU - Weber, Martin S.

AU - Zamvil, Scott S.

AU - Pacheco, Maria Fides Manago

AU - Menge, Til

AU - Hartung, Hans Peter

AU - Kieseier, Bernd C.

AU - Frohman, Elliot

PY - 2008

Y1 - 2008

N2 - Currently, six medications are approved by the US FDA for the treatment of relapsing forms of multiple sclerosis (MS). In contrast, no pharmacological agent has proved to be effective in patients with secondary-progressive MS without relapses, or in patients with primary-progressive MS. One of the principal issues concerning an optimal pharmacotherapy for relapsing forms of MS is the optimal time of treatment initiation. There is now an almost universal consensus among MS experts that many patients will benefit from early therapy. However, several formidable challenges exist in identifying individuals who will benefit versus those who will do well without intervention. How do we define early MS and what clinical and paraclinical markers may be useful in defining the timing and nature of therapy? Do patients with a benign form of MS require therapy or are they exposed unnecessarily to adverse effects of our currently available medications? How do we identify disease progression and treatment failures? This review discusses these issues and outlines the evidence for application of 'early' treatment in patients with relapsing forms of MS.

AB - Currently, six medications are approved by the US FDA for the treatment of relapsing forms of multiple sclerosis (MS). In contrast, no pharmacological agent has proved to be effective in patients with secondary-progressive MS without relapses, or in patients with primary-progressive MS. One of the principal issues concerning an optimal pharmacotherapy for relapsing forms of MS is the optimal time of treatment initiation. There is now an almost universal consensus among MS experts that many patients will benefit from early therapy. However, several formidable challenges exist in identifying individuals who will benefit versus those who will do well without intervention. How do we define early MS and what clinical and paraclinical markers may be useful in defining the timing and nature of therapy? Do patients with a benign form of MS require therapy or are they exposed unnecessarily to adverse effects of our currently available medications? How do we identify disease progression and treatment failures? This review discusses these issues and outlines the evidence for application of 'early' treatment in patients with relapsing forms of MS.

KW - Interferon beta 1a, therapeutic use

KW - Interferon beta 1b, therapeutic use

KW - Multiple sclerosis, treatment

UR - http://www.scopus.com/inward/record.url?scp=37249048528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249048528&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 73

EP - 83

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 1

ER -